Temat: "Receptor" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Autorzy :: Namisaki T; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. .
Kaji K; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Shimozato N; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Kaya D; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Ozutsumi T; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Tsuji Y; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Fujinaga Y; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Kitagawa K; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Furukawa M; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Sato S; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Sawada Y; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Nishimura N; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Takaya H; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Okura Y; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Seki K; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Kawaratani H; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Moriya K; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Noguchi R; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Asada K; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Akahane T; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Mitoro A; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.
Yoshiji H; Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan.; Pokaż więcej
Źródło :: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology [Indian J Gastroenterol] 2022 Apr; Vol. 41 (2), pp. 169-180. Date of Electronic Publication: 2022 Mar 12.
Typ publikacji :: Journal Article
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers*/pharmacology
Angiotensin II Type 1 Receptor Blockers*/therapeutic use
Non-alcoholic Fatty Liver Disease*/drug therapy
Non-alcoholic Fatty Liver Disease*/metabolism
Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Animals ; Humans ; Liver Cirrhosis/genetics ; Losartan/pharmacology ; Losartan/therapeutic use ; Matrix Metalloproteinase 2 ; RNA, Messenger/metabolism ; Rats ; Tissue Inhibitor of Metalloproteinase-1/therapeutic use ; Toll-Like Receptor 4 ; Transforming Growth Factor beta1/metabolism ; Transforming Growth Factor beta1/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Variations within Toll-like receptor (TLR) and TLR signaling pathway-related genes and their synergistic effects on the risk of Guillain-Barré syndrome.
Autorzy :: Dutta D; Department of Human Genetics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Nagappa M; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Sreekumaran Nair BV; Department of Biostatistics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Das SK; Department of Biostatistics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Wahatule R; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Sinha S; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Vasanthapuram R; Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Taly AB; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.
Debnath M; Department of Human Genetics, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India.; Pokaż więcej
Źródło :: Journal of the peripheral nervous system : JPNS [J Peripher Nerv Syst] 2022 Jun; Vol. 27 (2), pp. 131-143. Date of Electronic Publication: 2022 Feb 23.
Typ publikacji :: Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms :: Guillain-Barre Syndrome*/genetics
Toll-Like Receptor 2*/genetics
Toll-Like Receptor 2*/metabolism
Adaptor Proteins, Vesicular Transport/genetics ; Adaptor Proteins, Vesicular Transport/pharmacology ; Case-Control Studies ; Genetic Predisposition to Disease/genetics ; Humans ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/pharmacology ; NF-KappaB Inhibitor alpha/genetics ; Polymorphism, Single Nucleotide ; Signal Transduction/genetics ; TNF Receptor-Associated Factor 3/genetics ; TNF Receptor-Associated Factor 3/pharmacology ; TNF Receptor-Associated Factor 6/genetics ; TNF Receptor-Associated Factor 6/pharmacology ; Toll-Like Receptor 3/genetics ; Toll-Like Receptor 4/genetics ; Toll-Like Receptor 4/metabolism ; Toll-Like Receptors/genetics
: Raport

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: mRNA expression of toll-like receptors 3, 7, 8, and 9 in the nasopharyngeal epithelial cells of coronavirus disease 2019 patients.
Autorzy :: Bagheri-Hosseinabadi Z; Pistachio Safety Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.; Department of Clinical Biochemistry, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Rezazadeh Zarandi E; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.; Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Mirabzadeh M; Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Amiri A; Department of Orthodontics, College of Stomatology, The First Affiliated Stomatological Hospital, Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China.
Abbasifard M; Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. .; Department of Internal Medicine, Ali-Ibn Abi-Talib Hospital, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. .; Pokaż więcej
Źródło :: BMC infectious diseases [BMC Infect Dis] 2022 May 10; Vol. 22 (1), pp. 448. Date of Electronic Publication: 2022 May 10.
Typ publikacji :: Journal Article
MeSH Terms :: COVID-19*
Toll-Like Receptor 3*/genetics
Toll-Like Receptor 3*/metabolism
Epithelial Cells/metabolism ; Humans ; Nasopharynx ; RNA, Messenger/genetics ; Toll-Like Receptor 7/genetics ; Toll-Like Receptor 8/genetics ; Toll-Like Receptor 9/genetics ; Toll-Like Receptors/genetics
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 4 4.

Tytuł :: Defining Steric Requirements at CB 1 and CB 2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues.
Autorzy :: Markham J; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Chemistry, The University of Sydney, Sydney 2006, New South Wales, Australia.
Sparkes E; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Chemistry, The University of Sydney, Sydney 2006, New South Wales, Australia.
Boyd R; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Chemistry, The University of Sydney, Sydney 2006, New South Wales, Australia.
Chen S; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
Manning JJ; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
Finlay D; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
Lai F; School of Pharmacy, The University of Sydney, Sydney 2006, New South Wales, Australia.
McGregor E; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Psychology, The University of Sydney, Sydney 2005, New South Wales, Australia.
Maloney CJ; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Chemistry, The University of Sydney, Sydney 2006, New South Wales, Australia.
Gerona RR; Clinical Toxicology and Environmental Biomonitoring Laboratory, University of California, San Francisco, California 94143, United States.
Connor M; Faculty of Medicine and Health Sciences, Macquarie University, Sydney 2109, New South Wales, Australia.
McGregor IS; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Psychology, The University of Sydney, Sydney 2005, New South Wales, Australia.
Hibbs DE; School of Pharmacy, The University of Sydney, Sydney 2006, New South Wales, Australia.
Glass M; Department of Pharmacology and Toxicology, University of Otago, Dunedin 9016, New Zealand.
Kevin RC; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Pharmacy, The University of Sydney, Sydney 2006, New South Wales, Australia.
Banister SD; The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney 2050, New South Wales, Australia.; School of Chemistry, The University of Sydney, Sydney 2006, New South Wales, Australia.; Pokaż więcej
Źródło :: ACS chemical neuroscience [ACS Chem Neurosci] 2022 Apr 20; Vol. 13 (8), pp. 1281-1295. Date of Electronic Publication: 2022 Apr 11.
Typ publikacji :: Journal Article
MeSH Terms :: Cannabinoid Receptor Agonists*/chemistry
Cannabinoid Receptor Agonists*/pharmacology
Cannabinoids*/chemistry
Animals ; Central Nervous System Agents ; Indazoles/chemistry ; Indazoles/pharmacology ; Mice ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2 ; Receptors, Cannabinoid ; Valine/analogs & derivatives
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: In vitro pharmacological profile of PHA-022121, a small molecule bradykinin B 2 receptor antagonist in clinical development.
Autorzy :: Lesage A; Pharvaris GmbH., Zug, Switzerland. Electronic address: .
Marceau F; Département de Microbiologie, Infectiologie et Immunologie, Faculté de médecine, Université Laval, Québec, QC G1V 4G2, Canada.
Gibson C; AnalytiCon Discovery GmbH, Potsdam, Germany.
Loenders B; Pharvaris Netherlands B.V., Leiden, the Netherlands.
Katzer W; AnalytiCon Discovery GmbH, Potsdam, Germany.
Ambrosi HD; AnalytiCon Discovery GmbH, Potsdam, Germany.
Saupe J; AnalytiCon Discovery GmbH, Potsdam, Germany.
Faussner A; Faculty of Medicine, Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany.
Pardali E; Pharvaris Netherlands B.V., Leiden, the Netherlands.
Knolle J; Pharvaris GmbH., Zug, Switzerland.; Pokaż więcej
Źródło :: International immunopharmacology [Int Immunopharmacol] 2022 Apr; Vol. 105, pp. 108523. Date of Electronic Publication: 2022 Jan 24.
Typ publikacji :: Journal Article
MeSH Terms :: Bradykinin*/metabolism
Bradykinin Receptor Antagonists*/metabolism
Bradykinin Receptor Antagonists*/pharmacology
Animals ; Binding, Competitive ; Dogs ; Macaca fascicularis/metabolism ; Mammals ; Mice ; Rabbits ; Rats ; Receptor, Bradykinin B1/metabolism ; Receptor, Bradykinin B2/metabolism ; Umbilical Veins/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: ZBP1 promotes inflammatory responses downstream of TLR3/TLR4 via timely delivery of RIPK1 to TRIF.
Autorzy :: Muendlein HI; Department of Immunology, Tufts University School of Medicine, Boston, MA 02111.
Connolly WM; Department of Immunology, Tufts University School of Medicine, Boston, MA 02111.
Magri Z; Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, MA 02111.
Jetton D; Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, MA 02111.
Smirnova I; Department of Immunology, Tufts University School of Medicine, Boston, MA 02111.
Degterev A; Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA 02111.
Balachandran S; Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111.
Poltorak A; Department of Immunology, Tufts University School of Medicine, Boston, MA 02111.; Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, Boston, MA 02111.; Pokaż więcej
Źródło :: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2022 Jun 14; Vol. 119 (24), pp. e2113872119. Date of Electronic Publication: 2022 Jun 06.
Typ publikacji :: Journal Article
MeSH Terms :: Inflammation*/metabolism
Toll-Like Receptor 3*/metabolism
Toll-Like Receptor 4*/metabolism
Adaptor Proteins, Vesicular Transport/metabolism ; Animals ; Lipopolysaccharides/toxicity ; Mice ; RNA, Double-Stranded ; RNA-Binding Proteins/metabolism ; Receptor-Interacting Protein Serine-Threonine Kinases/genetics ; Receptor-Interacting Protein Serine-Threonine Kinases/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects.
Autorzy :: Tehrani AY; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
White Z; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
Tung LW; School of Biomedical Engineering and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Zhao RRY; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
Milad N; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
Seidman MA; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
Sauge E; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
Theret M; School of Biomedical Engineering and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Rossi FMV; School of Biomedical Engineering and Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Esfandiarei M; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.; Department of Biomedical Sciences, College of Graduate Studies, Midwestern University, Glendale, AZ, USA.
van Breemen C; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada.
Bernatchez P; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada. .; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Room 217, Vancouver, BC, V6T 1Z3, Canada. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2022 Jun 13; Vol. 12 (1), pp. 9771. Date of Electronic Publication: 2022 Jun 13.
Typ publikacji :: Journal Article
MeSH Terms :: Angiotensin II Type 1 Receptor Blockers*/pharmacology
Angiotensin Receptor Antagonists*
Angiotensin II/metabolism ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Animals ; Mice ; Nitric Oxide/metabolism ; Receptor, Angiotensin, Type 1/genetics ; Receptor, Angiotensin, Type 1/metabolism ; Telmisartan/pharmacology ; Vascular Remodeling
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 8 8.

Tytuł :: Discovery of Novel Bicyclic Phenylselenyl-Containing Hybrids: An Orally Bioavailable, Potential, and Multiacting Class of Estrogen Receptor Modulators against Endocrine-Resistant Breast Cancer.
Autorzy :: Deng X; College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China.
Xie B; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Li Q; College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China.
Xiao Y; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Hu Z; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Deng X; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Fang P; Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, China.
Dong C; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Zhou HB; State Key Laboratory of Virology, Frontier Science Center for Immunology and Metabolism, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Donghu Road, Wuhan 430071, China.
Huang J; College of Life Sciences, Wuhan University, Bayi Road, Wuhan 430072, China.; Pokaż więcej
Źródło :: Journal of medicinal chemistry [J Med Chem] 2022 Jun 09; Vol. 65 (11), pp. 7993-8010. Date of Electronic Publication: 2022 May 24.
Typ publikacji :: Journal Article
MeSH Terms :: Breast Neoplasms*/pathology
Estrogen Receptor Modulators*/pharmacology
Estrogen Receptor Modulators*/therapeutic use
Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Estrogen Receptor alpha/metabolism ; Female ; Humans ; MCF-7 Cells ; Selective Estrogen Receptor Modulators/pharmacology ; Selective Estrogen Receptor Modulators/therapeutic use ; Tamoxifen/pharmacology ; Tamoxifen/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A 2B adenosine receptor antagonists.
Autorzy :: Vlachodimou A; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
de Vries H; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Pasoli M; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Goudswaard M; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands.
Kim SA; Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Kim YC; Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Scortichini M; Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Marshall M; Department of Internal Medicine and Molecular Physiology & Biological Physics, University of Virginia Health Science Center, Charlottesville, VA 22908, USA.
Linden J; Department of Internal Medicine and Molecular Physiology & Biological Physics, University of Virginia Health Science Center, Charlottesville, VA 22908, USA.
Heitman LH; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands; Oncode Institute, Leiden, the Netherlands.
Jacobson KA; Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: .
IJzerman AP; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, P.O. Box 9502, 2300 RA Leiden, the Netherlands. Electronic address: .; Pokaż więcej
Źródło :: Biochemical pharmacology [Biochem Pharmacol] 2022 Jun; Vol. 200, pp. 115027. Date of Electronic Publication: 2022 Apr 06.
Typ publikacji :: Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :: Purinergic P1 Receptor Antagonists*
Xanthines*/pharmacology
Adenosine A2 Receptor Antagonists/pharmacology ; Kinetics ; Radioligand Assay ; Receptor, Adenosine A2B/metabolism ; Receptors, Purinergic P1/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
Autorzy :: Hattori N; Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Yamada A; Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Nakatsuji S; Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Matsuda T; Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Nishiyama N; Department of Pharmaceutical Sciences, Ritsumeikan University, Shiga, Japan.
Shimatsu A; Advanced Medical Care Center, Omi Medical Center, Shiga, Japan.; Pokaż więcej
Źródło :: Journal of molecular endocrinology [J Mol Endocrinol] 2022 May 10; Vol. 69 (1), pp. 259-268. Date of Electronic Publication: 2022 May 10.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Adiponectin*/metabolism
Angiotensin Receptor Antagonists*/metabolism
Angiotensin Receptor Antagonists*/pharmacology
Adipocytes/metabolism ; Angiotensin II Type 1 Receptor Blockers/metabolism ; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/metabolism ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Benzoates/metabolism ; Benzoates/pharmacology ; Humans ; Inflammation/metabolism ; Irbesartan/pharmacology ; Leptin/metabolism ; PPAR alpha/metabolism ; PPAR gamma/metabolism ; RNA, Messenger/metabolism ; Telmisartan/metabolism ; Telmisartan/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: A 2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
Autorzy :: Spinaci A; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Lambertucci C; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Buccioni M; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Dal Ben D; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Graiff C; Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze, 17/A, 43124 Parma, Italy.
Barbalace MC; Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.
Hrelia S; Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.
Angeloni C; Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, Corso d'Augusto 237, 47921 Rimini, Italy.
Tayebati SK; Pharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Ubaldi M; Pharmacology Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Masi A; Departiment of Neuroscience, Psychology, Drug Research and Child's Health, NEUROFARBA, Università di Firenze, 50139 Firenze, Italy.
Klotz KN; Institut für Pharmakologie und Toxikologie, University of Würzburg, Versbacher Straße 9, D-97078 Würzburg, Germany.
Volpini R; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.
Marucci G; Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, 62032 Camerino, Italy.; Pokaż więcej
Źródło :: Molecules (Basel, Switzerland) [Molecules] 2022 Apr 07; Vol. 27 (8). Date of Electronic Publication: 2022 Apr 07.
Typ publikacji :: Journal Article
MeSH Terms :: Adenosine A2 Receptor Antagonists*/chemistry
Adenosine A2 Receptor Antagonists*/pharmacology
Purinergic P1 Receptor Antagonists*/pharmacology
Purines/chemistry ; Receptor, Adenosine A2A/metabolism ; Structure-Activity Relationship
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 12 12.

Tytuł :: Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury.
Autorzy :: Nakamura T; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France.
Bonnard B; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France.
Palacios-Ramirez R; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France.
Fernández-Celis A; Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
Jaisser F; Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, 75006 Paris, France.; INSERM, Clinical Investigation Centre 1433, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT (Cardiovascular and Renal Clinical Trialists), 54500 Nancy, France.
López-Andrés N; Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 15; Vol. 23 (12). Date of Electronic Publication: 2022 Jun 15.
Typ publikacji :: Journal Article
MeSH Terms :: Kidney Diseases*/etiology
Toll-Like Receptor 4*/metabolism
Aldosterone/metabolism ; Aldosterone/pharmacology ; Animals ; Biglycan/metabolism ; Eplerenone/pharmacology ; Mice ; Mineralocorticoid Receptor Antagonists/pharmacology ; NF-kappa B/metabolism ; Receptors, Mineralocorticoid/metabolism ; Signal Transduction ; Sodium Chloride, Dietary ; Tumor Necrosis Factor-alpha
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Acute serotonin 1B/1A receptor activation impairs behavioral flexibility in C57BL/6J mice.
Autorzy :: Oliver BL; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Burdette MH; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Pahua AE; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Cavazos C; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Morales CA; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Alvarez BD; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.
Amodeo DA; California State University, San Bernardino, Department of Psychology, 5500 University Parkway, San Bernardino, CA 92407, USA.; Pokaż więcej
Źródło :: Behavioural brain research [Behav Brain Res] 2022 Jun 03; Vol. 427, pp. 113865. Date of Electronic Publication: 2022 Mar 30.
Typ publikacji :: Journal Article
MeSH Terms :: Receptor, Serotonin, 5-HT1A*
Serotonin*/pharmacology
Animals ; Female ; Male ; Mice ; Mice, Inbred C57BL ; Receptor, Serotonin, 5-HT1B ; Receptors, Serotonin, 5-HT1 ; Serotonin 5-HT1 Receptor Agonists/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Estrogen receptor α activation modulates the gut microbiome and type 2 diabetes risk factors.
Autorzy :: Shiffler JA; Exercise and Sport Sciences Department, Augustana University, Sioux Falls, South Dakota, USA.
Goerger KA; Biology Department, University of Sioux Falls, Sioux Falls, South Dakota, USA.
Gorres-Martens BK; Exercise and Sport Sciences Department, Augustana University, Sioux Falls, South Dakota, USA.; Pokaż więcej
Źródło :: Physiological reports [Physiol Rep] 2022 Jun; Vol. 10 (11), pp. e15344.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2*
Estrogen Receptor alpha*/agonists
Estrogen Receptor alpha*/metabolism
Gastrointestinal Microbiome*
Animals ; Estradiol/metabolism ; Estrogen Receptor beta/agonists ; Estrogen Receptor beta/metabolism ; Female ; PPAR alpha ; PPAR gamma ; Rats ; Rats, Wistar ; Risk Factors
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 15 15.

Tytuł :: A patent review of adenosine A 2B receptor antagonists (2016-present).
Autorzy :: Francucci B; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Dal Ben D; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Lambertucci C; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Spinaci A; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Volpini R; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Marucci G; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.
Buccioni M; School of Pharmacy, Medicinal Chemistry Unit, University of Camerino, Camerino, Italy.; Pokaż więcej
Źródło :: Expert opinion on therapeutic patents [Expert Opin Ther Pat] 2022 Jun; Vol. 32 (6), pp. 689-712. Date of Electronic Publication: 2022 Apr 07.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2*/drug therapy
Receptor, Adenosine A2B*/chemistry
Receptor, Adenosine A2B*/physiology
Adenosine/pharmacology ; Adenosine A2 Receptor Antagonists/pharmacology ; Adenosine A2 Receptor Antagonists/therapeutic use ; Humans ; Patents as Topic ; Signal Transduction
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Effects of selective orexin receptor-2 and cannabinoid receptor-1 antagonists on the response of medial prefrontal cortex neurons to tramadol.
Autorzy :: Hasanpour Razmanjani N; Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Reisi P; Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.; Pokaż więcej
Źródło :: Synapse (New York, N.Y.) [Synapse] 2022 Jun; Vol. 76 (7-8), pp. e22232. Date of Electronic Publication: 2022 Mar 29.
Typ publikacji :: Journal Article
MeSH Terms :: Orexin Receptor Antagonists*/pharmacology
Tramadol*/pharmacology
Animals ; Cannabinoid Receptor Antagonists/pharmacology ; Endocannabinoids ; Male ; Neurons ; Orexin Receptors/metabolism ; Prefrontal Cortex/metabolism ; Rats ; Receptor, Cannabinoid, CB1 ; Receptors, Cannabinoid
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: The Effects of Mannuronic Acid on IL-1β, IL-17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis.
Autorzy :: Najafi S; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Saadat P; Mobility Impairment Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Beladi Moghadam N; Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Science, Tehran, Iran.
Manoucherinia A; Department of Clinical Neuroscience (CNS), Karolinska Institutet, Stockholm, Sweden.
Aghazadeh Z; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Vali Mohammadi A; Shiraz Branch, Islamic Azad University, Shiraz, Iran.
Noorbakhsh SM; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Movahedi M; Department of Biochemistry, Faculty of Life Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Nikouei Moghaddam MR; Department of Biochemistry, Faculty of Life Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Pashaiefar H; Hematology, Oncology and Stem cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mirshafiey A; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.; Pokaż więcej
Źródło :: Journal of clinical pharmacology [J Clin Pharmacol] 2022 Jun; Vol. 62 (6), pp. 762-769. Date of Electronic Publication: 2022 Jan 07.
Typ publikacji :: Journal Article
MeSH Terms :: Multiple Sclerosis*/drug therapy
Multiple Sclerosis*/genetics
Multiple Sclerosis*/metabolism
Toll-Like Receptor 2*/genetics
Toll-Like Receptor 2*/metabolism
Clinical Trials, Phase II as Topic ; Gene Expression ; Hexuronic Acids ; Humans ; Interleukin-17/genetics ; Leukocytes, Mononuclear/metabolism ; STAT1 Transcription Factor/genetics ; STAT1 Transcription Factor/metabolism ; STAT1 Transcription Factor/pharmacology ; STAT3 Transcription Factor/genetics ; STAT3 Transcription Factor/metabolism ; Toll-Like Receptor 4/genetics ; Toll-Like Receptor 4/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer.
Autorzy :: Topcu KSB; Department of Molecular Biology and Genetics, Faculty of Science, Bartın University, Bartın, Turkey.
Korucu EN; Department of Molecular Biology and Genetics, Faculty of Science, Necmettin Erbakan University, Konya, Turkey. .
Menevse E; Department of Medical Biochemistry, Faculty of Medicine, Selcuk University, Konya, Turkey.
Kocak N; Department of Medical Genetics, Faculty of Medicine, Selcuk University, Konya, Turkey.
Duran T; Department of Medical Genetics, Faculty of Medicine, KTO Karatay University, Konya, Turkey.; Pokaż więcej
Źródło :: Investigational new drugs [Invest New Drugs] 2022 Jun; Vol. 40 (3), pp. 519-528. Date of Electronic Publication: 2022 Feb 03.
Typ publikacji :: Journal Article
MeSH Terms :: Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/immunology
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/immunology
Pancreatic Neoplasms*/metabolism
Toll-Like Receptor 4*/antagonists & inhibitors
Toll-Like Receptor 4*/immunology
Toll-Like Receptor 4*/metabolism
B7 Antigens ; Humans ; Interleukin-1 Receptor-Associated Kinases/immunology ; Interleukin-1 Receptor-Associated Kinases/metabolism ; Naloxone/pharmacology ; RNA, Small Interfering
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Autorzy :: Tsai HC; Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.; Graduate Institute of Clinical Medical Sciences and School of Traditional Chinese Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Wei KC; Department of Neurosurgery, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital, New Taipei Municipal, Taipei, 236, Taiwan.; Department of Neurosurgery, Keelung Chang Gung Memorial Hospital, Keelung, 204, Taiwan.
Chen PY; Department of Neurosurgery, Keelung Chang Gung Memorial Hospital, Keelung, 204, Taiwan.; School of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Huang CY; Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.; School of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Chen KT; Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.; School of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Lin YJ; Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.; School of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
Cheng HW; Department of Neurosurgery, Linkou Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan.; Department of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.; Department of Pharmacology, National Yang-Ming University, Taipei, 112, Taiwan.
Huang CH; Department of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
Wang HT; Department of Pharmacology, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan. .; Department of Pharmacology, National Yang-Ming University, Taipei, 112, Taiwan. .; Pokaż więcej
Źródło :: Neuromolecular medicine [Neuromolecular Med] 2022 Jun; Vol. 24 (2), pp. 113-124. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Brain Neoplasms*/drug therapy
Brain Neoplasms*/genetics
Glioblastoma*/drug therapy
Glioblastoma*/genetics
Glioma*/drug therapy
Glioma*/genetics
Nuclear Receptor Co-Repressor 1*/genetics
Nuclear Receptor Co-Repressor 1*/metabolism
Temozolomide*/pharmacology
Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; E2F1 Transcription Factor/genetics ; E2F1 Transcription Factor/metabolism ; Gene Expression Regulation, Neoplastic ; Humans ; Nuclear Receptor Interacting Protein 1
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A 2A Receptor with Preladenant Conjugates.
Autorzy :: Claff T; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Klapschinski TA; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Tiruttani Subhramanyam UK; Centre for Structural Systems Biology (CSSB), Notkestraße 85, 22607, Hamburg, Germany.; Research Centre Jülich, Institute of Complex Systems (IBI-7), Wilhelm-Johnen-Straße, 52425, Jülich, Germany.
Vaaßen VJ; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Schlegel JG; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Vielmuth C; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Voß JH; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
Labahn J; Centre for Structural Systems Biology (CSSB), Notkestraße 85, 22607, Hamburg, Germany.; Research Centre Jülich, Institute of Complex Systems (IBI-7), Wilhelm-Johnen-Straße, 52425, Jülich, Germany.
Müller CE; Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.; Pokaż więcej
Źródło :: Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2022 May 23; Vol. 61 (22), pp. e202115545. Date of Electronic Publication: 2022 Mar 24.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Point Mutation*
Receptor, Adenosine A2A*/chemistry
Adenosine ; Adenosine A2 Receptor Antagonists ; Humans ; Pyrimidines ; Triazoles/chemistry
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Receptor"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język